Author: admin

“Treatment-resistant Hypertension Drugs Market”

(Albany, USA) DelveInsight’s ‘Treatment-resistant Hypertension Market Insights, Epidemiology, and Market Forecast 2034’ report deliver an in-depth understanding of Treatment-resistant Hypertension, historical and forecasted epidemiology, as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

The Treatment-resistant Hypertension market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Treatment-resistant Hypertension market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Treatment-resistant Hypertension treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Treatment-resistant Hypertension market.

Explore the intricate details of the Treatment-Resistant Hypertension Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Treatment-Resistant Hypertension Market Forecast. Click here to stay ahead in healthcare innovation @ Treatment-Resistant Hypertension Market Size

Key Takeaways from the Treatment-Resistant Hypertension Market Report

• April 2024:- United Therapeutics- A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH.
• According to Delveinsight estimates in 2023, the total prevalent cases of RHTN were the highest in the US, with ~10,004,000 cases, and is lowest in the United Kingdom with ~600,000 cases.
• According to DelveInsight’s analysis, RHTN is more prevalent in females as compared to males. DelveInsight’s epidemiology model for RHTN estimates that in the US, ~44% of cases were males, and ~55% were females in 2023.
• The leading Treatment-Resistant Hypertension Companies such as Idorsia Ltd, Janssen Biotech, Quantum Genomics SA, CinCor Pharma, Ionis Pharmaceuticals, Vifor Pharma, KBP Biosciences, and others.
• Promising Treatment-resistant Hypertension Therapies such as Ralinepag, aprocitentan, CIN-107, and others.

Treatment-resistant Hypertension overview

Treatment-resistant hypertension (TRH) is a condition where blood pressure (BP) remains above the target levels despite adherence to a regimen of at least three antihypertensive medications, including a diuretic, at optimal doses. It affects approximately 10-20% of individuals with hypertension and poses a significant risk for cardiovascular diseases such as stroke, heart attack, and kidney failure.

Treatment-resistant Hypertension may result from various factors, including secondary hypertension causes like obstructive sleep apnea, chronic kidney disease, or primary aldosteronism. Medication non-adherence, suboptimal treatment regimens, and lifestyle factors such as high sodium intake, obesity, and excessive alcohol consumption can also contribute.

Proper Treatment-resistant Hypertension diagnosis involves ruling out pseudoresistance, which can arise from measurement errors or white-coat hypertension. Managing Treatment-resistant Hypertension requires a multifaceted approach, including optimizing pharmacotherapy, lifestyle modifications, and addressing underlying secondary causes. Emerging treatments, such as renal denervation and baroreceptor activation therapy, are being explored for patients unresponsive to traditional therapies.

Given its complexity and significant health implications, Treatment-resistant Hypertension demands careful evaluation and a personalized management plan, underscoring the importance of collaboration between patients and healthcare providers. Early intervention and adherence to therapy can significantly improve outcomes and reduce cardiovascular risks.

Navigate the complexities of the Treatment-Resistant Hypertension Market: Gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Treatment-Resistant Hypertension Market Forecast. Click here to get more insights @ Treatment-Resistant Hypertension Treatment Market

Treatment-Resistant Hypertension Epidemiology Segmentation in the 7MM

• Total Treatment-Resistant Hypertension Prevalent Cases
• Treatment-Resistant Hypertension Gender-specific Cases
• Treatment-Resistant Hypertension Age-specific Cases

Treatment-Resistant Hypertension Emerging Drugs Profile

• Aprocitentan: Idorsia Ltd/Janssen Biotech

Aprocitentan is an investigational, orally active dual endothelin receptor antagonist in development for the RHTN (individuals with uncontrolled hypertension despite the use of at least three antihypertensive drugs).

• Firibastat (QGC001): Quantum Genomics SA

The firibastat (originally named QGC001) product is a prodrug that delivers in the brain the EC33 product, a selective and specific inhibitor of Aminopeptidase A, thus preventing the production of Angiotensin III in the brain. Due to its unique action mechanism, firibastat represents an alternative therapeutic approach that can interfere with the mechanism involved in the genesis and control of blood pressure in hypertensive patients, especially those with a particular hormonal profile, characterized by a low renin concentration and a high vasopressin concentration (Low Renin High Vasopressin (LRHV) profile). Firibastat and its therapeutic use are strongly protected by several families of patents ensuring industrial protection until 2033 without considering the potential additional protection certificates.

• CIN-107: CinCor Pharma

CIN-107 is a highly selective aldosterone synthase inhibitor being developed for large unmet medical needs, including resistant hypertension and primary aldosteronism. CIN-107 works through the renin-angiotensin-aldosterone system (RAAS), which regulates the body’s fluid and electrolyte balance.

Delve deep into the Treatment-Resistant Hypertension Market Landscape: Analyze drug adoption, treatment paradigms, and epidemiological shifts in our detailed Treatment-Resistant Hypertension Market Forecast. Click here to shape the future @ Treatment-Resistant Hypertension Epidemiology Insights

Treatment-Resistant Hypertension Treatment Landscape

The main treatment strategies adopted for Treatment-resistant hypertension are withdrawal of interfering medication, diuretic therapy, mineralocorticoids, combination therapy, and the use of spironolactone as the fourth agent for treating RHTN. Nonpharmacological interventions including lifestyle changes: weight loss; regular exercise; ingestion of a high-fiber, low-fat, low-salt diet; and moderation of alcohol intake should be encouraged where appropriate. Potentially interfering drug substances should be withdrawn or down-titrated as clinically allowable. If present, obstructive sleep apnea should be treated. Other promising treatment include device-based intervention, including renal denervation, Carotid sinus stimulators, and Central arteriovenous fistula placement, among others.

Unlock insights into the Treatment-Resistant Hypertension Market: discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Treatment-Resistant Hypertension Market Forecast. Click here @ Treatment-Resistant Hypertension Market Drivers and Barriers

Treatment-Resistant Hypertension Market Insights

Hypertension is the most common modifiable risk factor for cardiovascular disease and death, and lowering blood pressure with antihypertensive drugs reduces target organ damage and prevents cardiovascular disease outcomes. Despite a plethora of available treatment options, a substantial portion of the hypertensive population has uncontrolled blood pressure.

Scope of the Treatment-Resistant Hypertension Market Report

• Coverage- 7MM
• Treatment-Resistant Hypertension Companies- Idorsia Ltd, Janssen Biotech, Quantum Genomics SA, CinCor Pharma, Ionis Pharmaceuticals, Vifor Pharma, KBP Biosciences, and others.
• Treatment-resistant Hypertension Therapies- Ralinepag, aprocitentan, CIN-107, and others.
• Treatment-Resistant Hypertension Market Dynamics: Treatment-Resistant Hypertension Market drivers and Treatment-Resistant Hypertension Market Barriers
• Treatment-Resistant Hypertension Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Treatment-Resistant Hypertension Unmet Needs, KOL’s views, Analyst’s views, Treatment-Resistant Hypertension Market Access and Reimbursement

Gain a strategic edge in the Treatment-Resistant Hypertension Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Treatment-Resistant Hypertension Market Forecast. Click here to lead in advancements @ Treatment-Resistant Hypertension Clinical Trials Assessment

Table of Content

1. Key Insights

2. Report Introduction

3. Treatment-resistant Hypertension (RHTN) Market Overview at a Glance

4. Executive Summary of Treatment-resistant Hypertension

5. Disease Background and Overview

6. Epidemiology and Patient Population

7. Patient Journey

8. Emerging Therapies

9. Other Promising Therapies

10. Treatment-resistant Hypertension (RHTN): 7 Major Market Analysis

11. SWOT Analysis

12. Unmet Needs

13. KOL Views

14. Appendix

15. DelveInsight Capabilities

16. Disclaimer

17. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Treatment-resistant Hypertension Drugs Market 2034: FDA Approvals, Clinical Trials, Medication, and Companies by DelveInsight

“Systemic Sclerosis Market”

(Albany, USA) DelveInsight’s Systemic Sclerosis Market Insights report includes a comprehensive understanding of current treatment practices, systemic sclerosis emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Takeaways from the Systemic Sclerosis Market Report

• According to DelveInsight’s analysis, the market size for systemic sclerosis is expected to grow significantly by 2034.
• Systemic sclerosis usually appears in women aged 30–40, and it occurs in slightly older men. In approximately 85% of cases, systemic sclerosis develops in individuals aged 20–60 years.
• Leading systemic sclerosis companies such as Kyowa Hakko Kirin, AstraZeneca, Cabaletta Bio, Mitsubishi Tanabe Pharma, Genentech, Inc., Amgen, GlaxoSmithKline, Boehringer Ingelheim, and others are developing novel systemic sclerosis drugs that can be available in the systemic sclerosis market in the coming years.
• The promising systemic sclerosis therapies in the pipeline include Brodalumab, Anifrolumab, CABA-201, Inebilizumab, RO7303509, HZN-825, Belimumab, Avenciguat (BI 685509), and others.
• In March 2024, CABA-201 received an Orphan Drug Designation (ODD) for the treatment of systemic sclerosis. In addition, it has also been granted Fast Track Designation (FTD) by the US FDA in January 2024 for the same.

Discover which therapies are expected to grab the major systemic sclerosis market share @ Systemic Sclerosis Market Report

Systemic Sclerosis Overview

Systemic sclerosis, also known as scleroderma, is a chronic autoimmune disease characterized by the hardening and tightening of the skin and connective tissues. The condition arises due to the overproduction and accumulation of collagen in the skin and internal organs, leading to fibrosis. The exact cause of systemic sclerosis is not well understood, but it is believed to involve a combination of genetic predisposition and environmental factors, which trigger an abnormal immune response.

Symptoms of systemic sclerosis vary widely depending on the organs affected and the severity of the disease. Common symptoms include skin thickening and hardening, particularly on the fingers, hands, and face, Raynaud’s phenomenon, and joint pain. As the disease progresses, it can affect internal organs, leading to complications such as esophageal dysfunction, pulmonary fibrosis, renal crisis, and heart issues.

Diagnosing systemic sclerosis involves a combination of clinical evaluation, laboratory tests, and imaging studies. A physical examination often reveals characteristic skin changes and blood tests may show specific autoantibodies, such as anti-centromere or anti-topoisomerase I (Scl-70) antibodies. Imaging techniques like high-resolution computed tomography (HRCT) of the lungs and echocardiography can assess the extent of internal organ involvement. A skin biopsy may also be performed to confirm the diagnosis by showing typical histopathological changes associated with the disease.

Systemic Sclerosis Epidemiology Segmentation

The systemic sclerosis epidemiology section provides insights into the historical and current systemic sclerosis patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.

The systemic sclerosis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Diagnosed Prevalent Cases of Systemic Sclerosis
• Gender-specific cases of Systemic Sclerosis
• Age-specific cases of Systemic Sclerosis
• Type-specific cases of Systemic Sclerosis
• Severity-specific cases of Systemic Sclerosis
• Complications Associated with Systemic Sclerosis 

Systemic Sclerosis Treatment Market 

While no treatment has been shown to alter the overall progression of the disease, the therapy aims to address specific organ involvement early on to prevent irreversible damage, enhancing both quality of life and survival. Disease-modifying drugs can be recommended based on the clinical presentation and potential visceral damage. Special attention should be given to symptomatic drug treatments. Hematopoietic stem cell transplantation may be an option for patients with rapidly progressing systemic sclerosis who are at risk of organ failure, but it should only be performed at high-volume centers.

The treatment of systemic sclerosis is tailored to address specific manifestations such as skin, lung, gastric, heart, and kidney issues. Most therapies aim to treat the affected organs to prevent irreversible damage and to enhance both quality of life and survival. The primary manifestations of SSc are cutaneous and pulmonary and recommended treatments include Intravenous Cyclophosphamide, Methotrexate, Mycophenolate Mofetil, or Azathioprine. Cyclophosphamide is particularly prescribed for improving skin conditions in patients with SSc-associated interstitial lung disease.

For scleroderma pulmonary fibrosis, antifibrotic therapies like D-penicillamine, Esbriet (pirfenidone), and Ofev (nintedanib) are utilized. Raynaud’s phenomenon (RP) and digital ulcers are commonly treated with calcium-channel blockers, phosphodiesterase 5 inhibitors, and angiotensin-converting enzyme inhibitors.

In cases of severe diffuse cutaneous SSc (dcSSc), autologous hematopoietic stem cell transplantation has been shown to improve patient survival, cutaneous symptoms, pulmonary involvement, and overall quality of life.

To know more about systemic sclerosis treatment guidelines, visit @ Systemic Sclerosis Management 

Systemic Sclerosis Pipeline Therapies and Key Companies

Some of the drugs in the pipeline include Brodalumab (Kyowa Hakko Kirin), Anifrolumab (AstraZeneca), CABA-201 (Cabaletta Bio), and Inebilizumab (Mitsubishi Tanabe Pharma), among others.

Brodalumabis is an innovative monoclonal antibody that functions as an Interleukin 17 receptor antagonist, targeting the inflammatory cytokine pathway. It blocks Interleukin 17 interactions with cytokines IL-17A, IL-17F, IL-17C, IL-17A/F heterodimer, and IL-25. Kyowa Kirin submitted a supplemental New Drug Application (sNDA) to Japan’s Ministry of Health, Labour and Welfare (MHLW) in December 2021, based on Phase III study results in Japanese patients with systemic sclerosis, characterized by moderate to severe skin sclerosis. In June 2022, the company presented the positive outcomes from this Phase III study at the EULAR (European Alliance of Associations for Rheumatology) 2022 Congress.

CABA-201, a fully human CD19-CAR T cell investigational therapy that includes a 4-1BB component, is engineered to deplete CD19-positive B cells deeply and temporarily after a single infusion. This approach aims to “reset” the immune system, potentially leading to long-term remission without ongoing therapy for patients with autoimmune diseases. In October 2023, the US FDA approved the IND application for CABA-201 for a Phase I/II study targeting systemic sclerosis. By March 2024, the drug was granted an Orphan Drug Designation (ODD) for systemic sclerosis treatment. Additionally, it received Fast Track Designation (FTD) from the US FDA in January 2024 for the same condition. The company has started a Phase I/II open-label study (RESET-SSc) of CABA-201 in systemic sclerosis patients, dividing participants into two parallel cohorts: six patients with severe skin involvement and six patients with pulmonary, cardiac, or renal involvement, regardless of skin condition.

The other therapies in the pipeline include 

• RO7303509: Genentech, Inc.
• HZN-825: Amgen
• Belimumab: GlaxoSmithKline
• Avenciguat (BI 685509): Boehringer Ingelheim

The anticipated launch of these emerging therapies for systemic sclerosis are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the systemic sclerosis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Discover more about systemic sclerosis drugs in development @ Systemic Sclerosis Clinical Trials 

Systemic Sclerosis Market Dynamics

The dynamics of the systemic sclerosis market are expected to change in the coming years. Based on the role of B cells and the published clinical data with CD19-CAR T therapy in systemic sclerosis, it is believed that CABA-201 may transform the treatment for systemic sclerosis. Kyowa Kirin submitted an sNDA for brodalumab in treating systemic sclerosis, and the launch of this drug will boost the systemic sclerosis market. Additionally, the development of a potential biomarker that allows for tracking and predicting the severity and potential progress of the disease, as well as the effectiveness of any therapeutic intervention, is crucial. Since pulmonary involvement is a leading cause of morbidity and mortality in systemic sclerosis, there is a need for more effective treatments that can stabilize or improve lung function and delay disease progression.

Furthermore, potential therapies are being investigated for the treatment of systemic sclerosis, and it is safe to predict that the treatment space will significantly impact the systemic sclerosis market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the systemic sclerosis market in the 7MM.

However several factors may impede the growth of the systemic sclerosis market. Only 35–50% of systemic sclerosis patients are eligible for current treatment, and while ERT has shown benefits mostly in kidney disease and reduction in left ventricular hypertrophy, it has not demonstrated dramatic improvement in outcomes for all organ systems. Additionally, reimbursement challenges, including limited coverage by healthcare payers or restrictive reimbursement policies, may limit patient access to expensive SSc therapies.

Moreover, systemic sclerosis treatment poses a significant economic burden and disrupts patients’ overall well-being and QOL. Furthermore, the systemic sclerosis market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the systemic sclerosis market growth.

Learn more about the emerging Systemic Sclerosis therapies & key companies @ Systemic Sclerosis Treatment Market

Scope of the Systemic Sclerosis Market Report

• Study Period: 2020–2034
• Coverage: 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].
• Key Systemic Sclerosis Companies: Kyowa Hakko Kirin, AstraZeneca, Cabaletta Bio, Mitsubishi Tanabe Pharma, Genentech, Inc., Amgen, GlaxoSmithKline, Boehringer Ingelheim, and others
• Key Pipeline Systemic Sclerosis Therapies: Brodalumab, Anifrolumab, CABA-201, Inebilizumab, RO7303509, HZN-825, Belimumab, Avenciguat (BI 685509), and others
• Therapeutic Assessment: Systemic Sclerosis current marketed and emerging therapies
• Systemic Sclerosis Market Dynamics: Key Market Forecast Assumptions of Emerging Systemic Sclerosis Drugs and Market Outlook
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL’s views, Analyst’s views, Systemic Sclerosis Market Access and Reimbursement

Download the report to understand which factors are driving systemic sclerosis market trends @ Systemic Sclerosis Market Trends

Table of Contents

1. Systemic Sclerosis Key Insights

2. Systemic Sclerosis Report Introduction

3. Systemic Sclerosis Overview at a Glance

4. Systemic Sclerosis Executive Summary

5. Systemic Sclerosis Key Events

6. Epidemiology and Market Forecast Methodology

6. Disease Background and Overview

7. Systemic Sclerosis Treatment and Management

8. Systemic Sclerosis Guidelines

9. Systemic Sclerosis Epidemiology and Patient Population

10. Patient Journey

11. Key Endpoints in Systemic Sclerosis

12. Systemic Sclerosis Marketed Drugs

13. Systemic Sclerosis Emerging Drugs

14. 7MM Systemic Sclerosis Market Analysis

15. Market Access and Reimbursement

16. KOL Views

17. Unmet Needs

18. SWOT Analysis

19. Appendix

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Systemic Sclerosis Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, Epidemiology, Medication, and Companies by DelveInsight

“IgG4-related disease Treatment Market”

(Albany, USA) DelveInsight’s “IgG4-related disease Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of IgG4-related disease, historical and forecasted epidemiology as well as the IgG4-related disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The IgG4-related disease market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted IgG4-related disease market size from 2020 to 2034, segmented by seven major markets. The Report also covers current IgG4-related disease treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the IgG4-related disease market.

Request for a Free Sample Report @ IgG4-related disease Market Forecast

Some facts of the IgG4-related disease Market Report are:

• The IgG4-Related Disease market size is anticipated to grow with a significant CAGR during the study period (2020-2034).
• IgG4 related disease is a systemic disease that causes fibrosis, tumor-like nodules, and lymphoid hyperplasia with infiltration of IgG4-positive plasma cells. It can manifest in many organ systems.
• There are no approved therapies for IgG4-related disease (IgG4-RD) specifically and hence, the current treatment landscape is driven by off-label therapies such as glucocorticoids, immunomodulators, and rituximab.
• The market size of IgG4-related disease in the seven major markets (7MM) was around USD 150 million in 2023.
• Glucocorticoids (GCs) have been considered the first-line therapy in IgG4-related disease (IgG4-RD), whereas rituximab accounted for the majority of the market share as annual treatment cost is significantly higher for patients taking rituximab.
• The United States accounted for the largest market size (around USD 115 million) of IgG4-related disease treatment market, in comparison to EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
• Limited number of therapies are being investigated for the treatment of IgG4 related disease. Some of the key players involved in the development are Zenas Biopharma (obexelimab), Amgen/Horizon Therapeutics (inebilizumab), and Sanofi (rilzabrutinib).
• Approval of ZB012 (obexelimab) and UPLIZNA (inebilizumab) will change the treatment pattern drastically over the forecast period as these will be the first few drugs to be launched for the treatment of IgG4-related disease.
• IgG4-related disease is a rare disease, with an estimated prevalence of 6 cases per 100,000 individuals. This condition primarily affects middle-aged to elderly men.
• The 7MM accounted for approximately 300,000 prevalent cases of IgG4-related disease in 2023. These cases are expected to increase due to increased awareness and improved diagnostic methods that contribute to the rise in identified cases of IgG4-related disease, especially among aging populations with higher incidences of autoimmune disorders.
• Key IgG4-Related Disease Companies: Zenas BioPharma, Horizon Therapeutics, Sanofi, Roche, AbbVie, Gilead Sciences, Takeda Pharmaceutical Company, and others
• Key IgG4-Related Disease Therapies: ZB012 (obexelimab), UPLIZNA (inebilizumab), Rilzabrutinib, and others
• The IgG4-Related Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage IgG4-Related Disease pipeline products will significantly revolutionize the IgG4-Related Disease market dynamics.
• Zenas BioPharma’s INDIGO Trial: Zenas BioPharma is conducting the Phase III INDIGO trial to evaluate the safety and efficacy of obexelimab in patients with active IgG4-RD. The trial has completed targeted enrollment with approximately 190 patients across 100 sites in 20 countries2. The trial includes a randomized controlled period (RCP) followed by an optional open-label extension (OLE) period.
• Amgen’s MITIGATE Trial: Amgen reported positive topline outcomes from the Phase III MITIGATE trial assessing UPLIZNA (inebilizumab-cdon). The trial met its primary endpoint, demonstrating an 87% decline in flare risk versus placebo. The trial enrolled 135 adults across 80 sites in 22 countries1. The results were published on June 6, 2024.

IgG4-related disease Overview

IgG4-related disease (IgG4-RD) is a rare, chronic, and often systemic inflammatory condition characterized by tissue infiltration with IgG4-positive plasma cells, fibrosis, and swelling in affected organs. It can involve multiple systems, including the pancreas, bile ducts, salivary glands, kidneys, lungs, lymph nodes, and blood vessels, presenting as painless swelling or masses.

The disease’s exact cause is unknown but is thought to involve a combination of autoimmune and allergic mechanisms. Elevated serum IgG4 levels are commonly observed, though not always present. Common manifestations include autoimmune pancreatitis, sclerosing cholangitis, retroperitoneal fibrosis, or orbital pseudotumors, depending on the organs involved.

Diagnosis is challenging and relies on a combination of clinical features, imaging, biopsy findings (showing lymphoplasmacytic infiltration, storiform fibrosis, and IgG4-positive cells), and elevated IgG4 levels. Ruling out malignancies and other autoimmune diseases is crucial due to overlapping symptoms.

Treatment typically involves corticosteroids to reduce inflammation and swelling, often leading to significant improvement. In refractory cases, immunosuppressive agents like rituximab may be used. Early diagnosis and intervention are essential to prevent permanent organ damage. Long-term monitoring is necessary, as the disease may relapse or involve additional organs over time.

Do you know what will be the IgG4-related disease market share in 7MM by 2034 @ IgG4-related disease Treatment Market

IgG4-related disease Market 

The IgG4-related disease market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted IgG4-related disease market trends by analyzing the impact of current IgG4-related disease therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the IgG4-related disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated IgG4-related disease market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the IgG4-related disease market in 7MM is expected to witness a major change in the study period 2020-2034.

IgG4-related disease Epidemiology

The IgG4-related disease epidemiology section provides insights into the historical and current IgG4-related disease patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the IgG4-related disease market report also provides the diagnosed patient pool, trends, and assumptions. 

Interested to know how the emerging diagnostic approaches will be contributing in increased IgG4-related disease diagnosed prevalence pool? Download report @ https://www.delveinsight.com/report-store/igg4-related-disease-market

IgG4-related disease Drugs Uptake

This section focuses on the uptake rate of the potential IgG4-related disease drugs recently launched in the IgG4-related disease market or expected to be launched in 2020-2034. The analysis covers the IgG4-related disease market uptake by drugs, patient uptake by therapies, and sales of each drug.   

IgG4-related disease Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on IgG4-related disease market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

IgG4-related disease Pipeline Development Activities

The IgG4-related disease report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses IgG4-related disease key players involved in developing targeted therapeutics.

Download report to know which TOP 3 therapies will be capturing the largest IgG4-related disease market share by 2034? Click here @ IgG4-related disease Medication and Companies

IgG4-related disease Therapeutics Assessment

Major key companies are working proactively in the IgG4-related disease Therapeutics market to develop novel therapies which will drive the IgG4-related disease treatment markets in the upcoming years are Zenas BioPharma, Horizon Therapeutics, Sanofi, Roche, AbbVie, Gilead Sciences, Takeda Pharmaceutical Company, and others.

Do you know how new drugs market launch will be impacting the IgG4-related disease market CAGR? Download sample report @ IgG4-related disease Drugs Market

IgG4-related disease Report Key Insights

1. IgG4-related disease Patient Population

2. IgG4-related disease Market Size and Trends

3. Key Cross Competition in the IgG4-related disease Market

4. IgG4-related disease Market Dynamics (Key Drivers and Barriers)

5. IgG4-related disease Market Opportunities

6. IgG4-related disease Therapeutic Approaches

7. IgG4-related disease Pipeline Analysis

8. IgG4-related disease Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the IgG4-related disease Market

Table of Contents

1. Key Insights

2. Executive Summary

3. IgG4-related disease Competitive Intelligence Analysis

4. IgG4-related disease Market Overview at a Glance

5. IgG4-related disease Disease Background and Overview

6. IgG4-related disease Patient Journey

7. IgG4-related disease Epidemiology and Patient Population

8. IgG4-related disease Treatment Algorithm, Current Treatment, and Medical Practices

9. IgG4-related disease Unmet Needs

10. Key Endpoints of IgG4-related disease Treatment

11. IgG4-related disease Marketed Products

12. IgG4-related disease Emerging Therapies

13. IgG4-related disease Seven Major Market Analysis

14. Attribute Analysis

15. IgG4-related disease Market Outlook (7 major markets)

16. IgG4-related disease Access and Reimbursement Overview

17. KOL Views on the IgG4-related disease Market

18. IgG4-related disease Market Drivers

19. IgG4-related disease Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/market-assessment-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: IgG4-related disease Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, Epidemiology, Medication, and Companies by DelveInsight